Evoke Pharma (EVOK) Posts Smaller-than-Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
March 7, 2018 4:05 PM ESTSuccessfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti doseAnnounced discovery of sex-based pharmacokinetic differences for GimotiMet with FDA regarding NDA women-only filing strategy and post-marketing plans505(b)(2) NDA submission planned for second quarter of 2018Â Â Â Â Â Â Â
SOLANA BEACH, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and full year ended... More
